[HTML][HTML] Preclinical Alzheimer's disease and longitudinal driving decline
CM Roe, GM Babulal, DM Head, SH Stout… - Alzheimer's & Dementia …, 2017 - Elsevier
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2017•Elsevier
Abstract Introduction Links between preclinical Alzheimer's disease (AD) and driving
difficulty onset would support the use of driving performance as an outcome in primary and
secondary prevention trials among older adults (OAs). We examined whether AD
biomarkers predicted the onset of driving difficulties among OAs. Methods One hundred four
OAs (65+ years) with normal cognition took part in biomarker measurements, a road test,
clinical and psychometric batteries, and self-reported their driving habits. Results Higher …
difficulty onset would support the use of driving performance as an outcome in primary and
secondary prevention trials among older adults (OAs). We examined whether AD
biomarkers predicted the onset of driving difficulties among OAs. Methods One hundred four
OAs (65+ years) with normal cognition took part in biomarker measurements, a road test,
clinical and psychometric batteries, and self-reported their driving habits. Results Higher …
Introduction
Links between preclinical Alzheimer's disease (AD) and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving difficulties among OAs.
Methods
One hundred four OAs (65+ years) with normal cognition took part in biomarker measurements, a road test, clinical and psychometric batteries, and self-reported their driving habits.
Results
Higher values of cerebrospinal fluid (CSF) tau/Aβ42 and phosphorylated tau (ptau181)/Aβ42 ratios, but not uptake on Pittsburgh compound B amyloid imaging (P = .12), predicted time to a rating of marginal or fail on the driving test using Cox proportional hazards models. Hazards ratios (95% confidence interval) were 5.75 (1.70–19.53), P = .005 for CSF tau/Aβ42; 6.19 (1.75–21.88), and P = .005 for CSF ptau181/Aβ42.
Discussion
Preclinical AD predicted time to receiving a marginal or fail rating on an on-road driving test. Driving performance shows promise as a functional outcome in AD prevention trials.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果